The Biofactory is steering innovations in diagnostic technologies for trinucleotide repeat disorders. Though these disorders are inheritable and can be passed from parent to offspring, none of the current diagnostic techniques can achieve large-scale, rapid screening.
The Biofactory has developed the FastFraX™ line of kits for rapid, large-scale screening and diagnosis of a major trinucleotide repeat disorder, Fragile X syndrome. Fragile X syndrome is characterized by intellectual disability and autism-like behavior.
An X-linked disorder, Fragile X syndrome affects nearly twice as many males as females. More importantly, as many as 1 in 250 females and 1 in 486 males are carriers of a pre-mutated form of the gene, which can expand into the full mutant form when passed to their offspring.
The FastFraX™ Identification Kit will enable large-scale carrier screening of trinucleotide repeat disorders to facilitate family planning or genetic counseling. Subsequent kits for confirming the repeat size and methylation status of the gene for Fragile X are also in development.